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Abstract
Background and Aim: Inflammatory bowel disease (IBD) is associated with an increased risk of colorectal cancer (CRC).
Studies have shown tumorigenetic and histomorphological differences between IBD-associated CRC and non-IBD CRC,
suggesting differences in tumor behavior and response to treatment. We aimed to compare tumor recurrence and survival
rates following postoperative chemotherapy in CRC patients with and without IBD.
Methods: Search of the Cleveland Clinic’s CRC database revealed 65 patients who had IBD-associated CRC and received
postoperative adjuvant chemotherapy between 1994 and 2010. Twenty-one patients were excluded due to incomplete
clinical data. Propensity score-matching based on age, surgery intent, CRC site, tumor grade, American Joint Committee on
Cancer (AJCC) stage and T stage was used to match IBD and non-IBD patients (1:4). Competing risk and Cox regression mod-
els were used to analyze differences in disease-free survival and overall survival, respectively.
Results: Forty-four patients with IBD-associated CRC were matched to 176 patients with non-IBD CRC. Among IBD patients,
29 (66%) had ulcerative colitis, 14 (32%) had Crohn’s disease, and one (2%) had indeterminate colitis. Mean IBD diagnosis age
was 28.16 14.5 years, and mean IBD duration at time of CRC treatment was 21.56 12.6 years. Ten (23%) IBD patients had
tumor recurrence compared with 34 (19%) non-IBD patients (P ¼ .074). There was no significant difference in disease-free
survival (hazard ratio [HR] ¼ 0.60; 95% CI: 0.35–1.05; P ¼ 0.074) or overall survival (HR¼0.87; 95% CI: 0.54–1.4; P ¼ 0.58)
between IBD and non-IBD patients.
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Conclusion: Patients with IBD-associated CRC have comparable rates of tumor recurrence and survival following
postoperative chemotherapy as CRC patients without IBD. Prospective studies are needed to confirm these findings
and guide therapeutic decisions.
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INTRODUCTION
Colorectal cancer (CRC) is currently the third most common
cancer in both males and females, and the second leading cause
of cancer-related deaths in the United States [1]. Worldwide,
CRC is responsible for about 600, 000 deaths every year [2].
While most cases of CRC are sporadic, 1–2% of CRC patients
have underlying inflammatory bowel disease (IBD), either ul-
cerative colitis (UC) or Crohn’s disease (CD). IBD patients have
an increased risk of developing CRC compared with the general
population, and IBD-associated CRC tends to be difficult to treat
and carries a higher mortality rate compared with sporadic CRC
[3,4]. The overall prevalence of CRC in UC patients with pancoli-
tis is in the range of 4–5%, with a similar percentage observed in
CD patients who have severe, long-standing colitis in the ab-
sence of bowel resection [5].
The association between CRC and IBD is well established in pa-
tients with colitis due to either UC or CD [6]. Specific molecular sig-
naling pathways have been linked to the development of sporadic
CRC, while additional pathways—including unique ones—have
been implicated in the carcinogenesis of IBD-associated CRC [7].
IBD patients tend to have excessive inflammatory cell infiltration
and increased expression of a number of inflammatory genes [8].
This mucosal inflammation promotes cellular proliferation and
ultimately the development of CRC. Further evidence for the
inflammation-to-cancer cascade came from studies demonstrat-
ing a protective role for anti-inflammatory medications such as
non-steroidal anti-inflammatory drugs and 5-aminosalicylic acid,
which were shown to reduce the risk of colitis-related CRC [9].
Given the tumorigenetic and histomorphological differences
between IBD-associated and sporadic CRC, differences in tumor
behavior could be present and potentially affect the response to
treatment. The aim of this study was to assess differences in
tumor recurrence and survival rates following postoperative
chemotherapy in CRC patients with and without IBD in order to
determine the potential need for tailored management of
patients with IBD-associated CRC.
PATIENTS ANDMETHODS
Study population
After obtaining institutional review board approval, the
Cleveland Clinic’s prospectively maintained CRC database was
accessed. Adult patients were identified who had been diag-
nosed with CRC, underwent surgical treatment for CRC and sub-
sequently received postoperative chemotherapy between 1994
and 2010. Baseline patient characteristics including the pres-
ence or absence of underlying IBD were recorded. Patients with
incomplete clinical data were excluded. All patients were staged
according to the 7th edition of the American Joint Committee
on Cancer (AJCC) staging system [10].
Patient matching
A propensity score was used to match each patient with IBD-
associated CRC to 4 non-IBD patients with CRC. A logistic
regression model was used to create the propensity score,
which included the following variables: age at time of surgical
treatment, intent of surgery (curative vs palliative), site of CRC
(colon, rectum), grade of tumor differentiation, AJCC stage and
T stage. The probability of having IBD was used as the propen-
sity score, and a greedy matching algorithm was used to find
the best matches for each IBD patient. Median difference in pro-
pensity score between matches was 0.001 (25th, 75th percent-
iles: 0.001, 0.02).
Statistical analysis
Mean 6 standard deviation or median (25th, 75th percentiles)
were used for continuous variables and N (%) for categorical fac-
tors. A univariable analysis was performed to assess differences
between CRC patients with and without IBD. Analysis of vari-
ance or non-parametric Kruskal-Wallis tests were used for con-
tinuous or ordinal variables, and Pearson chi-square tests were
used for categorical factors. A time-event-analysis was used to
assess overall survival and disease-free survival following surgi-
cal treatment of CRC. Follow-up time for overall survival was
defined as months from surgery to death or last follow-up if
event-free at end of the follow-up period. Follow-up time for
disease-free survival was defined as months from surgery to
disease recurrence, disease-unrelated death or last follow-up if
event-free at end of follow-up period.
Kaplan-Meier plots were constructed, and regression models
were used to compare the groups while adjusting for the pro-
pensity score. Competing risk and multivariable Cox regression
models were used to analyze the differences in disease-free sur-
vival and overall survival, respectively, between CRC patients
with and without IBD. For the competing risks analysis, patients
were censored if they died from other reasons or if they re-
mained alive at the last follow-up. A P value < 0.05 was con-
sidered statistically significant. All analyses were performed
using SAS version 9.2 (SAS Institute, Cary, NC) and R version
3.0.2 (R Foundation for Statistical Computing, Vienna).
RESULTS
A total of 65 patients with IBD-associated CRC who received
postoperative chemotherapy were identified. After excluding 21
patients due to lack of complete clinical data; 44 patients with
IBD-associated CRC who received postoperative chemotherapy
were matched to 176 non-IBD patients with CRC who received
postoperative chemotherapy. The form of chemotherapy prior
to 2004 was fluorouracil, while most patients treated after 2004
received both fluorouracil and oxaliplatin.
Among 220 patients with CRC, 163 (75%) had colon cancer,
and 57 (25%) had rectal cancer. Of the IBD-associated CRC pa-
tients, 10 (23%) had tumor recurrence (3 local, 6 distant, 1 local
and distant) compared with 34 (19%) of non-IBD patients with
CRC (2 local, 25 distant, 7 local and distant) (P ¼ 0.074). Table 1
summarizes the characteristics of all CRC patients, comparing
patients with IBD-associated CRC with matched non-IBD CRC
patients.
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Of the IBD patients, 29 (66%) had UC, 14 (32%) had CD, and 1
(2%) had indeterminate colitis. All IBD-associated CRC cases
were confirmed by histologic review. Thirty-six patients had
available data on IBD treatment, and 26 of them (72%) were
receiving medical treatment for IBD at the time of CRC diagno-
sis. Six patients (14%) had synchronous primary sclerosing chol-
angitis (all with UC). Average age at time of IBD diagnosis was
28.1 6 14.5 years, and duration of IBD at time of CRC treatment
was 21.5 6 12.6 years. Table 2 summarizes the characteristics of
patients with IBD-associated CRC.
Crude mortality was observed in 52% of IBD-associated CRC
patients (mean follow-up: 74.1 6 58.9 months) and 49% of non-
IBD CRC patients (mean follow-up: 64.8 6 71.0 months) (P ¼
0.58). There was no significant difference in disease-free sur-
vival (HR ¼ 0.60; 95% confidence interval [CI]: 0.35–1.05; P ¼
0.074) or overall survival (HR¼ 0.87; 95% CI: 0.54–1.4; P ¼ 0.58) be-
tween IBD and non-IBD patients (Figure 1).
After adjusting for the propensity score, there was a trend
toward significance (P ¼ 0.060) suggesting that IBD patients
might have a better disease-free survival rate than non-IBD pa-
tients. Table 3 compares disease-free survival and overall
survival based on the IBD status and degree of tumor
differentiation.
DISCUSSION
IBD-associated CRC does not necessarily follow the typical
adenoma-to-cancer sequence of events as most cases of spor-
adic CRC [11]. The presence, degree, duration and anatomical
extent of colonic inflammation have been associated with the
risk of CRC in patients with IBD [12]. Chronic mucosal inflam-
mation is thought to result in gradual progression to dysplasia
and ultimately invasive CRC. A number of genomic disruptions
have been identified within cells from colonic mucosa of pa-
tients having chronic colitis including aneuploidy, aberrant
DNA methylation and p53 mutations [10,13,14].
Prognosis of patients with IBD-associated CRC has been
variably reported; some reports showed a prognosis compar-
able to sporadic CRC [15–17], while other reports suggested an
increased risk of death and decreased overall survival [18–23].
For example, in one report, stage III CRC patients with IBD in
particular showed significantly decreased survival (23.0 vs
133.9 months for patients with sporadic CRC), although most
patients in that study received chemotherapy with or without
radiation [23]. However, a direct comparison of tumor recur-
rence and survival rates following postoperative chemotherapy
in CRC patients with and without IBD has not been previously
reported.
In a prior study from our group, we demonstrated morpho-
logic similarity between IBD-associated CRC and microsatellite
instability high (MSI-H) CRC [24]. Sporadic MSI-H CRC is less re-
sponsive to fluorouracil treatment compared with sporadic
microsatellite stable (MSS) CRC [24]. In addition, patients with
IBD have been reported to have high risk of intestinal toxicity
(e.g. diarrhea) from fluorouracil-based chemotherapy [25].
Furthermore, the presence of PSC in patients with IBD-
associated CRC may result in increased risk of liver toxicity
specifically derived from fluorouracil-based chemotherapy.
Thus, our initial hypothesis was that patients with IBD-
associated CRC may have less response to fluorouracil-based
chemotherapy and thus worse prognosis than patients with
sporadic CRC.
In this matched case-control study, there were no differ-
ences in tumor recurrence rate, disease-free survival and overall
survival following postoperative chemotherapy in CRC patients
with and without IBD. These findings suggest that fluorouracil-
based chemotherapy is effective in IBD-associated CRC despite
its morphologic resemblance to MSI-H CRC. This seemingly






Age at time of
surgery (years)
51.46 12.5 50.1 6 13.0 0.55a
Male 131 (74) 32 (73) 0.82c
Intent of surgery 0.77c
Curative 151 (86) 37 (84)
Palliative 25 (14) 7 (16)
Site of CRC 0.88c
Colon 130 (74) 33 (75)
Rectal 46 (26) 11 (25)
AJCC stage 0.99b
I 4 (2) 1 (2)
II 29 (17) 8 (18)
III 118 (67) 28 (64)
IV 25 (14) 7 (16)
T stage 0.79b
T1 6 (3) 2 (5)
T2 27 (15) 5 (11)
T3 119 (68) 31 (70)
T4 24 (14) 6 (14)
Grade of differentiation 0.54b
Well 3 (2) 1 (2)
Moderate 95 (54) 21 (48)
Poor 78 (44) 22 (50)
Follow-up (months) 64.8 6 71.0 74.1 6 58.9 0.42a
Propensity score† 0.85 60.08 0.83 6 0.10 0.14a
Values presented as mean 6 standard deviation or number (column %).
P values:
a ¼ ANOVA,
b ¼ Kruskal-Wallis test,
c ¼ Pearson chi-square test.
†A logistic regression model was used to create the propensity score: age at time
of surgical treatment, intent of surgery, site of CRC, grade of tumor differenti-
ation, AJCC stage and T stage.
Table 2. IBD-associated CRC patient characteristics
Total (N¼ 44)




Indeterminate colitis 1 (2)
IBD activity at time of CRC diagnosis
Active 19 (43)
Inactive 23 (52)
No data 2 (5)
IBD treatment at time of CRC diagnosis
None 10 (22)
1 drug 13 (30)
2þ drugs 13 (30)
No data 8 (18)
Primary sclerosing cholangitis 6 (14)
IBD - surgery interval (years) 21.5 6 12.6
Values presented as mean 6 standard deviation or number (column %).
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contradictory result may be explained by MSI-H histologic
morphology of IBD-associated CRC being independent of MSI
status [24].
This is the largest study to date examining tumor recur-
rence, disease-free survival and overall survival in patients
with IBD-associated CRC in comparison with a matched large
control group of sporadic CRCs. A major strength of this study
is that all IBD-associated CRC cases were confirmed by histo-
logic review rather than clinical diagnosis alone. Limitations of
the study include its retrospective design and the exclusion of
21 patients due to incomplete clinical data. As with all retro-
spective studies, data can be limited by the quality and avail-
ability of the information found within the database and
medical records. In particular, although a fluorouracil-based
regimen is recorded in our prospectively maintained CRC data-
base, more detailed information regarding dosage, use of radi-
ation and toxicity were lacking in several patients. Specific
details of oxaliplatin use were not available since we included
CRC patients diagnosed and treated before and after 2004,
when oxaliplatin was added to fluorouracil regimens for stage
II/III CRC. However, prior clinical trials showed that oxaliplatin
affects disease-free survival only and not overall survival of
those patients [26], thereby minimizing the impact of this limi-
tation on our results.
In summary, our study showed no difference in tumor recur-
rence, disease-free survival and overall survival in patients with
IBD-associated CRC compared with non-IBD CRC patients fol-
lowing surgical resection and postoperative chemotherapy.
These results suggest that, as in sporadic CRC patients, those
with IBD-associated CRC should be considered for postoperative
chemotherapy after surgical resection if otherwise eligible for
such treatments. Large prospective studies are needed to con-
firm these findings.
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